Health Catalyst Inc stock (US42226A1079): shares edge higher as Nasdaq health-data name digests latest quarterly trends

Health Catalyst stock on Nasdaq traded slightly higher on Friday as investors in the United States continued to assess the health-data specialist’s latest quarterly results and updated guidance in a volatile healthcare IT segment.

Health Catalyst stock traded modestly higher on Nasdaq on Friday, as investors in the United States weighed the company’s most recent quarterly performance and outlook against a mixed backdrop for healthcare analytics and software names. The shares, listed under the ticker HCAT, changed hands on the Nasdaq Stock Market in USD during the session, with trading volumes broadly in line with recent averages according to exchange data as of late May 2026.

The stock has seen uneven performance over the past year, reflecting shifting risk appetite for smaller healthcare IT companies relative to the broader US equity benchmarks. Recent price data compiled by Investing.com show that Health Catalyst has lagged major indices such as the S&P 500 over a multi-year horizon, underlining how investor sentiment toward the name remains more cautious than for larger, diversified healthcare peers. The current move therefore comes with investors focused less on short-term swings and more on whether the latest earnings trajectory supports a gradual improvement in fundamentals.

From a US home-country perspective, Health Catalyst remains firmly anchored in the domestic healthcare technology ecosystem through its Nasdaq listing and a client base that includes health systems, payers and related providers. The stock continues to trade against a backdrop of heightened scrutiny for healthcare data platforms, as US regulators and hospital systems pay closer attention to data security, interoperability and value-based care outcomes. This positioning on the Nasdaq, alongside other health IT and analytics names, frames the way US investors interpret each quarterly update and sector signal.

While there was no new earnings release on Friday itself, the market reaction is still informed by the company’s latest reported quarter, which investors continue to analyze for trends in subscription revenue, professional services demand and progress toward profitability. According to recent market data summaries and earnings calendars, the company’s latest update earlier this year outlined continued efforts to balance growth investments with cost discipline, a theme that many US software and analytics providers have faced in the current macroeconomic environment. This longer-running digestion of the prior results helps explain why share-price moves in late May have been relatively contained rather than sharply directional.

At the same time, Health Catalyst continues to trade alongside a broader cohort of health-IT stocks that have been volatile through 2025 and into 2026, with investors selectively rewarding companies that can demonstrate durable recurring revenue and clear operating leverage. Comparative performance tools show that Health Catalyst’s share-price trajectory over the past two years has been weaker than that of the S&P 500 and some software benchmarks, emphasizing the importance of future quarterly reports in rebuilding confidence. The modest uptick in the session therefore reflects incremental repositioning rather than a decisive shift in market perception.

For German-speaking investors, Health Catalyst is also available via secondary trading venues such as Tradegate, typically in euro, although liquidity is lower than on the primary Nasdaq line. These secondary quotations give European investors additional access to the US-listed healthcare analytics name but do not replace the central role of the Nasdaq listing for price discovery and corporate communication. Cross-border interest in the shares often increases around earnings dates and sector conferences, when newsflow on US healthcare reform and digitalization trends is more intense.

The stock’s behavior in late May also sits against a backdrop of ongoing portfolio rotation within US healthcare, where some investors have shifted toward larger managed-care and diversified device companies with more predictable cash flows. Health Catalyst’s relatively small market capitalization and focus on data and analytics solutions make it more sensitive to swings in sentiment toward growth-oriented healthcare IT. This dynamic means the company’s next quarterly earnings release and any updated guidance on revenue growth, adjusted EBITDA and cash flow are likely to be closely watched for signals about the pace of its path toward sustainable profitability.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Health Catalyst Inc
• Sector/industry: Healthcare information technology and analytics
• Headquarters/country: Salt Lake City, United States
• Core markets: United States healthcare providers, payers and life-science customers
• Key revenue drivers: Analytics and data-platform subscriptions, associated professional services and outcome-improvement solutions for healthcare organizations
• Home exchange/listing venue: Nasdaq (HCAT)
• Trading currency: USD

Health Catalyst Inc: core business model

Health Catalyst focuses on providing healthcare organizations with cloud-based data platforms and analytics tools, generating most of its revenue from recurring software subscriptions supplemented by implementation and consulting services tied to measurable clinical and financial outcomes.

Valuation metrics and multiples for Health Catalyst Inc

On this Friday valuation check, market observers primarily look at Health Catalyst through the lens of revenue-based metrics rather than earnings-based ratios, reflecting the company’s stage in its profitability journey. For many healthcare IT and analytics peers, including names tracked alongside Health Catalyst in sector comparison tools, valuation discussions typically focus on enterprise-value-to-sales multiples, given that GAAP net income can still be negative or only marginally positive and price-to-earnings ratios are therefore less meaningful. In this context, investors compare Health Catalyst’s trading range with that of a basket of similar data and analytics providers to gauge whether the market is assigning a discount or premium relative to expected growth and margin expansion.

Sector data and peer comparisons on platforms such as Investing.com indicate that Health Catalyst’s share-price performance has underperformed broad indices like the S&P 500 over the past two years, which in turn often feeds into a relatively lower sales multiple versus faster-growing or more profitable healthcare software names. That gap can cut both ways: some investors see it as a reflection of execution risk and competitive pressure, while others view it as potential upside if management can deliver on revenue growth targets and demonstrate operating leverage in upcoming results. In the absence of a current dividend and with earnings-based valuation still in flux, the market’s focus for HCAT remains centered on how quickly recurring revenue scales, how stable the customer base proves to be and whether margin trends improve in line with or better than sector averages for healthcare analytics vendors.

Conclusion

Health Catalyst shares on Nasdaq traded slightly higher on Friday as US investors continued to digest the company’s latest quarterly performance and its implications for revenue growth and the path to profitability. In valuation terms, the market still tends to benchmark HCAT primarily on revenue and sales multiples rather than earnings-based ratios, reflecting the company’s development stage within the healthcare analytics space.

How the stock performs from here will likely depend on whether upcoming quarterly releases can show accelerating recurring revenue, improving margins and stronger cash-flow trends that might close the performance and valuation gap versus broader indices and selected healthcare IT peers. For now, the modest price move and stable trading volumes underline that many market participants remain in a wait-and-see mode, monitoring execution against the strategic plan while keeping an eye on the broader sector environment for healthcare data and analytics providers.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.